Aura Biosciences, Inc. (NASDAQ:AURA) Insider Sells $122,374.85 in Stock

Aura Biosciences, Inc. (NASDAQ:AURA) insider Los Pinos Elisabet De sold 15,955 shares of the business’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total transaction of $122,374.85. Following the transaction, the insider now directly owns 304,692 shares of the company’s stock, valued at approximately $2,336,987.64. This represents a 4.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Los Pinos Elisabet De also recently made the following trade(s):

• On Tuesday, October 29th, Los Pinos Elisabet De sold 9,200 shares of Aura Biosciences stock. The stock was sold at an average price of $10.74, for a total transaction of $98,808.00.

Aura Biosciences Price Performance

Shares of NASDAQ AURA opened at $8.10 on Friday. The company’s 50 day simple moving average is $8.45 and its 200 day simple moving average is $8.91. Aura Biosciences, Inc. has a fifty-two week low of $6.63 and a fifty-two week high of $12.38. The firm has a market capitalization of $404.60 million, a P/E ratio of -4.68 and a beta of 0.30.

Aura Biosciences (NASDAQ:AURA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.02. Sell-side analysts expect that Aura Biosciences, Inc. will post -1.67 EPS for the current fiscal year.

Wall Street Analyst Weigh In

AURA has been the topic of several research reports. BTIG Research boosted their price objective on shares of Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a report on Friday, October 18th. Cowen restated a “buy” rating on shares of Aura Biosciences in a report on Friday, October 18th. Scotiabank upped their target price on shares of Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a research note on Friday, October 18th. Finally, HC Wainwright reissued a “buy” rating and issued a $22.00 target price on shares of Aura Biosciences in a research note on Thursday, November 14th. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $23.00.

Institutional Investors Weigh In On Aura Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Long Focus Capital Management LLC increased its stake in Aura Biosciences by 113.4% in the 2nd quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock valued at $7,992,000 after buying an additional 561,766 shares during the last quarter. Franklin Resources Inc. increased its stake in Aura Biosciences by 14.8% in the 3rd quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company’s stock valued at $15,571,000 after buying an additional 215,597 shares during the last quarter. Wellington Management Group LLP acquired a new stake in Aura Biosciences in the 3rd quarter valued at $1,037,000. Barclays PLC increased its stake in shares of Aura Biosciences by 256.5% during the 3rd quarter. Barclays PLC now owns 61,010 shares of the company’s stock worth $544,000 after purchasing an additional 43,897 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of Aura Biosciences by 20.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company’s stock worth $1,892,000 after purchasing an additional 41,711 shares during the last quarter. 96.75% of the stock is currently owned by institutional investors and hedge funds.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.